HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.

Villacampa G, Pascual T, Tarantino P, Cortés J, Perez-García J, Llombart-Cussac A, Conte P, Mancino M, Guarneri V, Dieci MV, Waks AG, Schettini F, Brasó-Maristany F, Griguolo G, de Castro BA, Reboredo C, Antolín S, Bueno-Muiño C, Echavarría I, López-Tarruella S, Massarrah T, Del Monte-Millán M, Martín M, Buckingham W, Parker JS, Vivancos A, Polyak K, Filho OM, Wolff AC, DeMichele A, Tung NM, Perou CM, Paré L, Villagrasa P, Prat A, Tolaney SM

Open source

DOI: 10.1016/s1470-2045(25)00276-1
Published: 2025 Aug
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-25-00276-1,
  title = {HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.},
  author = {Villacampa G and Pascual T and Tarantino P and Cortés J and Perez-García J and Llombart-Cussac A and Conte P and Mancino M and Guarneri V and Dieci MV and Waks AG and Schettini F and Brasó-Maristany F and Griguolo G and de Castro BA and Reboredo C and Antolín S and Bueno-Muiño C and Echavarría I and López-Tarruella S and Massarrah T and Del Monte-Millán M and Martín M and Buckingham W and Parker JS and Vivancos A and Polyak K and Filho OM and Wolff AC and DeMichele A and Tung NM and Perou CM and Paré L and Villagrasa P and Prat A and Tolaney SM},
  year = {2025},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(25)00276-1},
  url = {https://doi.org/10.1016/s1470-2045(25)00276-1}
}

RIS

TY  - JOUR
TI  - HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.
AU  - Villacampa G
AU  - Pascual T
AU  - Tarantino P
AU  - Cortés J
AU  - Perez-García J
AU  - Llombart-Cussac A
AU  - Conte P
AU  - Mancino M
AU  - Guarneri V
AU  - Dieci MV
AU  - Waks AG
AU  - Schettini F
AU  - Brasó-Maristany F
AU  - Griguolo G
AU  - de Castro BA
AU  - Reboredo C
AU  - Antolín S
AU  - Bueno-Muiño C
AU  - Echavarría I
AU  - López-Tarruella S
AU  - Massarrah T
AU  - Del Monte-Millán M
AU  - Martín M
AU  - Buckingham W
AU  - Parker JS
AU  - Vivancos A
AU  - Polyak K
AU  - Filho OM
AU  - Wolff AC
AU  - DeMichele A
AU  - Tung NM
AU  - Perou CM
AU  - Paré L
AU  - Villagrasa P
AU  - Prat A
AU  - Tolaney SM
PY  - 2025
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(25)00276-1
UR  - https://doi.org/10.1016/s1470-2045(25)00276-1
ER  -

APA

G, V., T, P., P, T., J, C., J, P., A, L., P, C., M, M., V, G., MV, D., AG, W., F, S., F, B., G, G., BA, D. C., C, R., S, A., C, B., I, E., S, L., T, M., M, D. M., M, M., W, B., JS, P., A, V., K, P., OM, F., AC, W., A, D., NM, T., CM, P., L, P., P, V., A, P., & SM, T. (2025). HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(25)00276-1

Source records

pubmed · retrieved 2026-09-27T09:30:07.384Z